Birchview Capital, LP Zentalis Pharmaceuticals, Inc. Transaction History
Birchview Capital, LP
- $111 Million
- Q1 2025
A detailed history of Birchview Capital, LP transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Birchview Capital, LP holds 17,000 shares of ZNTL stock, worth $22,950. This represents 0.02% of its overall portfolio holdings.
Number of Shares
17,000
Previous 17,000
-0.0%
Holding current value
$22,950
Previous $51,000
47.06%
% of portfolio
0.02%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding ZNTL
# of Institutions
139Shares Held
61.1MCall Options Held
7.9KPut Options Held
42.5K-
Matrix Capital Management Company, LP Waltham, MA14MShares$18.8 Million6.94% of portfolio
-
Black Rock Inc. New York, NY4.82MShares$6.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.26MShares$4.4 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.07MShares$4.14 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA2.67MShares$3.61 Million0.01% of portfolio
About Zentalis Pharmaceuticals, Inc.
- Ticker ZNTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,983,600
- Market Cap $76.9M
- Description
- Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...